Personalized Medicine News and Research

RSS

Exosome Diagnostics announces expansion of scientific advisory board

Exosome Diagnostics, a leading developer of biofluid based molecular diagnostic tests for use in personalised medicine, today announced the appointments of Bob Carter MD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board (SAB).

24 May 2011

Variant of obesity gene may increase breast cancer risk

New research aimed to better identify the genetic factors that lead to breast cancer has uncovered a link between the fat mass and obesity associated gene and a higher incidence of breast cancer.

24 May 2011

Berkeley Lab scientists reveal how protein-making machine bends without breaking

It sounds like hype from a late-night infomercial: It can twist and bend without breaking! And wait, there's more: It could someday help you fend off disease!

20 May 2011

MDxHealth reduces first quarter net loss by 17%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011.

18 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

The University of Washington Center for Commercialization and Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, today announced the execution of a licensing agreement between the parties.

18 May 2011

$100,000 needed to analyze '$1,000' genetic data

Advances in technology have almost lifted the curtain on the long-awaited era of the "$1,000 genome" - a time when all the genes that make up a person can be deciphered for about that amount - compared to nearly $1 million a few years ago.

12 May 2011

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that applications for market approval for vemurafenib for the treatment of metastatic melanoma have been submitted to the U.S. Food and Drug Administration and the European Medicines Agency.

11 May 2011

FDA clears Affymetrix's new gene profiling reagents for use in microarray instrument system

Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.

9 May 2011

Research experts to speak at brain tumor educational conference

Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.

5 May 2011

ChipDX identifies gene expression signature in early-stage breast tumors

ChipDX LLC, a New York-based molecular diagnostics and personalized medicine research company, has discovered a gene expression signature present in the cells of early-stage breast tumors that indicates the chance of the tumor recurring within 10 years.

4 May 2011

Caliper first quarter revenue increases 25% to $35.8 million

Caliper Life Sciences, Inc., today reported its financial results for the first quarter of 2011. First quarter revenue increased to $35.8 million, or 25%, from $28.7 million in the same period of 2010.

2 May 2011

Michael Dell shows how information technology can improve efficiency, quality of care today

Michael Dell today shared his insights with healthcare executives on how information technology is being used to improve the efficiency and quality of care today and how IT can support future innovations in prevention, wellness and personalized medicine.

30 Apr 2011

Biodesix announces patient enrollment for VeriStrat CASTLE study in lung cancer

Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.

29 Apr 2011

Affymetrix reports total revenue of $73.7 million for first quarter 2011

Affymetrix, Inc., today reported its operating results for the first quarter of 2011. Total revenue for the quarter was $73.7 million, as compared to total revenue of $80.2 million in the first quarter of 2010.

28 Apr 2011

Parents may chose predictive genetic tests for their children

Parents offered genetic testing to predict their risks of common, adult-onset health conditions say they would also test their children. That is the finding of a new study published in the May issue of Pediatrics.

18 Apr 2011

GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel

An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the "one-size fits all" strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, for patients with high on-treatment platelet reactivity does not reduce the incidence on death, heart attacks and stent thrombosis after percutaneous coronary intervention.

16 Apr 2011

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

A novel brain tumor vaccine clinical trial study demonstrates a longer survival time in patients with glioblastoma, according to findings being presented at the 79th Annual Scientific Meeting of the American Association of Neurological Surgeons in Denver.

12 Apr 2011

CINJ experts to comment on vaccine therapy and biomedical informatics

April marks National Cancer Control Awareness Month, which focuses on the importance of prevention, treatment, and research. Making significant contributions in all of these areas is The Cancer Institute of New Jersey, one of the nation's 40 Comprehensive Cancer Centers as designated by the National Cancer Institute and the only such center in New Jersey.

11 Apr 2011

New point-of-care trial can reduce cost and length of studies

Doctors at the Veterans Affairs Boston Healthcare System are testing a new kind of clinical trial that's not only less costly but guides doctors to switch to the best treatment even before the trial is completed.

11 Apr 2011

Personalized Medicine News and Research

Exosome Diagnostics announces expansion of scientific advisory board

Variant of obesity gene may increase breast cancer risk

Berkeley Lab scientists reveal how protein-making machine bends without breaking

MDxHealth reduces first quarter net loss by 17%

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

$100,000 needed to analyze '$1,000' genetic data

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

FDA clears Affymetrix's new gene profiling reagents for use in microarray instrument system

Research experts to speak at brain tumor educational conference

ChipDX identifies gene expression signature in early-stage breast tumors

Caliper first quarter revenue increases 25% to $35.8 million

Michael Dell shows how information technology can improve efficiency, quality of care today

Biodesix announces patient enrollment for VeriStrat CASTLE study in lung cancer

Affymetrix reports total revenue of $73.7 million for first quarter 2011

Parents may chose predictive genetic tests for their children

GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

CINJ experts to comment on vaccine therapy and biomedical informatics

New point-of-care trial can reduce cost and length of studies

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News